|  |  |
| --- | --- |
| **Fluorescent Target Molecule (Protein) 1:** | |
| General information | |
| Name (full name and/or abbreviation) | SARS-CoV-2 (COVID-19) S protein |
| Uniprot accession code | QHD43416.1 |
| Biochemical details | |
| Domain boundaries | 16-1213 |
| Calculated molecular weight [kDa] | 138 |
| Details (SS bridges, mutations, glycosylation etc.) (if any) | glycosylation |
| Co-factors for binding/activity (e.g. Ca2+-dependent) | NA |
| Fusion protein with a tag? (His, Strep, etc.) | C-terminal His-tag |
| Availability and stability | |
| Supplier | Acro Biosystems |
| Purity | >95% as determined by SDS-PAGE, >90% as determined by SEC-MALS |
| Comments | |
|  | |
| Recommendations from Crelux | |
| Preferred constructs and sources:   1. Spike Active Trimer (alternative):    * Acro Biosystems SPN-C52H2    * Product SPN-C52H2 carries the following mutations      + R683A, R685A, K986P, V987P    * Limited stock available, but in our hands better than the superstable construct (SPN-C52H7) | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Small molecule (and protein) interactions to analyze:** | | | | |
|  | Titrant | Expected Kd or IC50 (if available) | Solubility in assay buffer (if available) | Comments |
| 1 | nanobody | nM range | NA | For assay setup – provided by client |
| 2 | ACE2 | 17 nM (determined in SPR) | NA | For assay setup – purchased by Crelux |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |
| 11 |  |  |  |  |
| 12 |  |  |  |  |
| 13 |  |  |  |  |
| 14 |  |  |  |  |
| 15 |  |  |  |  |
| 16 |  |  |  |  |
| 17 |  |  |  |  |
| 18 |  |  |  |  |
| 19 |  |  |  |  |
| 20 |  |  |  |  |